Floatz logo

Dasatinib

Metastasis

Amsterdam UMC, location VUmcSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
81/ 100

Competitive context

171 Active assets in the Metastasis cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Dasatinib is also rated in:

B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →
chronic myeloid leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →